Home › Funds › Balyasny Asset Management › MDGL
Balyasny Asset Management position in MDGL
MADRIGAL PHARMACEUTICALS INC · Health Care
Latest position (Q2 2026)79.01K sh
Reported value held$42.42M
Portfolio Weight0.06%
First reportedQ4 2022
Last changeNew
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2022 | 200 | $58.05K | New |
| Q3 2023 | 28.20K | $4.12M | New |
| Q2 2024 | 2.45K | $685.83K | New |
| Q3 2024 | 10.20K | $2.16M | Add |
| Q4 2024 | 15.53K | $4.79M | Add |
| Q1 2025 | 27.21K | $9.01M | Add |
| Q2 2025 | 34.50K | $10.44M | Add |
| Q3 2025 | 87.10K | $39.95M | Add |
| Q4 2025 | 2.00K | $1.16M | Reduce |
| Q2 2026 | 79.01K | $42.42M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding MDGL
- Vanguard Group 1.81M sh · $1.05B · Q4 2025
- Janus Henderson Group 2.02M sh · $1.05B · Q1 2026
- Paulson & Co 1.34M sh · $719.52M · Q2 2026
- BlackRock Inc 1.20M sh · $644.75M · Q2 2026
- Wellington Management Group 825.71K sh · $443.37M · Q2 2026
- Citadel Advisors 688.13K sh · $369.49M · Q2 2026
- UBS Group AG 401.71K sh · $215.70M · Q2 2026
- Geode Capital Management 374.88K sh · $201.34M · Q2 2026
- Fidelity Management & Research (FMR) 356.20K sh · $191.26M · Q2 2026
- Invesco Ltd 301.44K sh · $161.86M · Q2 2026
- Goldman Sachs Group 246.28K sh · $132.24M · Q2 2026
- Norges Bank Investment Management 213.89K sh · $114.85M · Q2 2026